@dermnppa
Dept. of Education Publishes Proposed Rule on Professional Loans, NP/PA Groups Respond - Dermatology Education Foundation
Dept. of Education Publishes Proposed Rule on Professional Loans, NP/PA Groups Respond - Dermatology Education Foundation
Related posts: Dermalorian™ Podcast Series: New Episode Dermalorian Webinar Explores Role for Biosimilars in Dermatology Dermalorian™ Podcast Series: Listen to the September Episode NP, PA Are Top Healthcare Jobs in the US
Register Now For DERM2026
Register Now For DERM2026
Data Show Combined Efficacy of Taltz Plus Zepbound in PsA - Dermatology Education Foundation
Data Show Combined Efficacy of Taltz Plus Zepbound in PsA - Dermatology Education Foundation
Related posts: Beware Coronary Dysfunction in Psoriasis Patients UCB’s Bimzelx Approved for Psoriasis 3 Novel Drugs Approved in Dermatology in 2023: FDA NDA Approvals Up vs. 2022 Johnson & Johnson’s Investigational Icotrokinra Effective for Psoriasis at High-Impact Sites
Investigational TYK2 Inhibitor from Alumis Performs Well in Phase 3 Trials for PsO - Dermatology Education Foundation
Investigational TYK2 Inhibitor from Alumis Performs Well in Phase 3 Trials for PsO - Dermatology Education Foundation
Related posts: FDA Considers Four New Indications for Bimzelx from UCB First-in-Class Oral IL-23 Inhibitor Performs Well in Psoriasis Phase 3 Study Links Abdominal Fat to Psoriasis Risk Therapeutic Roundup: Updates in Psoriasis and Skin Cancer
Johnson & Johnson to Advance Investigational SLE Treatment to Phase 3 - Dermatology Education Foundation
Johnson & Johnson to Advance Investigational SLE Treatment to Phase 3 - Dermatology Education Foundation
Related posts: New Insights on Alopecia Areata Comorbidities Comprehensive Meta-analysis Sheds Light on Safety of JAKs for Management of AD CMS Issues Permanent J-Code for Ycanth Novel Microneedle Patch Delivery Eyed for AA Treatment
Takeda: Oral Psoriasis Candidate Performs Well in Phase 3 Trials - Dermatology Education Foundation
Takeda: Oral Psoriasis Candidate Performs Well in Phase 3 Trials - Dermatology Education Foundation
Takeda plans to file an NDA with the FDA zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, based on positive topline results from phase 3 psoriasis trials just released. In the randomized, multicenter, double-blind, placebo- and active comparator-controlled studies of in adults with moderate-to-severe plaque psoriasis, zasocitinib was superior to placebo for the co-primary endpoints, static Physician Global Assessment (sPGA) 0/1 and Psoriasis Area and Severity Index (PASI) 75, at week 16, with a significantly greater PASI 75 response rate seen as early as week 4 and continuing to increase through week 24.
Investigational STAT6 Degrader Shows Promise for AD - Dermatology Education Foundation
Investigational STAT6 Degrader Shows Promise for AD - Dermatology Education Foundation
An investigational oral STAT6 degrader medicine developed by Kymera Therapeutics, Inc. and known as KT-621 was assessed for safety and tolerability and to demonstrate that it could achieve robust STAT6 degradation in both blood and skin, resulting in reductions in multiple Type 2 inflammatory biomarkers in circulation and in the transcriptome of active AD lesions.
THE DERMALORIAN PODCAST - Dermatology Education Foundation
THE DERMALORIAN PODCAST - Dermatology Education Foundation
DEFinitely E-Newsletter - Dermatology Education Foundation
DEFinitely E-Newsletter - Dermatology Education Foundation
Job Board - Dermatology Education Foundation
Job Board - Dermatology Education Foundation
View on mobile